Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Trial Profile

An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to an Intra-Cellular Therapies media release.
    • 11 Dec 2018 According to an Intra-Cellular Therapies media release, due to the favorable safety profile of lumateperone observed to date, the study has been extended to allow patients to stay on lumateperone for more than one year and study conduct is ongoing.
    • 11 Dec 2018 According to an Intra-Cellular Therapies media release, favorable results from the second part of this study were presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) (Hollywood, FL, 9-13th Dec 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top